Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.

Samuel J P MalkinMonika Russel-SzymczykGirtel LiidemannVallo VolkeBarnaby Hunt

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2018)

Novo Nordisk A/S. Plain language summary available for this article.

Keyphrases